756 related articles for article (PubMed ID: 16888652)
1. Drug-target residence time and its implications for lead optimization.
Copeland RA; Pompliano DL; Meek TD
Nat Rev Drug Discov; 2006 Sep; 5(9):730-9. PubMed ID: 16888652
[TBL] [Abstract][Full Text] [Related]
2. The importance of drug-target residence time.
Zhang R; Monsma F
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
[TBL] [Abstract][Full Text] [Related]
3. Conformational adaptation in drug-target interactions and residence time.
Copeland RA
Future Med Chem; 2011 Sep; 3(12):1491-501. PubMed ID: 21882942
[TBL] [Abstract][Full Text] [Related]
4. A rational approach to maximize success rate in target discovery.
Schneider M
Arch Pharm (Weinheim); 2004 Dec; 337(12):625-33. PubMed ID: 15597396
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Designing transient binding drugs: a new concept for drug discovery.
Ohlson S
Drug Discov Today; 2008 May; 13(9-10):433-9. PubMed ID: 18468561
[TBL] [Abstract][Full Text] [Related]
7. [Design of multiple targeted drugs].
Guo YS; Guo ZR
Yao Xue Xue Bao; 2009 Mar; 44(3):276-81. PubMed ID: 19449524
[TBL] [Abstract][Full Text] [Related]
8. Ligand-based vascular targeting of disease.
Rybak JN; Trachsel E; Scheuermann J; Neri D
ChemMedChem; 2007 Jan; 2(1):22-40. PubMed ID: 17154429
[TBL] [Abstract][Full Text] [Related]
9. Lead optimization via high-throughput molecular docking.
Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
[TBL] [Abstract][Full Text] [Related]
10. Computational chemistry approaches to drug discovery in signal transduction.
Fischer PM
Biotechnol J; 2008 Apr; 3(4):452-70. PubMed ID: 18412174
[TBL] [Abstract][Full Text] [Related]
11. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
Rajamani R; Good AC
Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
[TBL] [Abstract][Full Text] [Related]
12. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
13. The drug-target residence time model: a 10-year retrospective.
Copeland RA
Nat Rev Drug Discov; 2016 Feb; 15(2):87-95. PubMed ID: 26678621
[TBL] [Abstract][Full Text] [Related]
14. Lead optimization in the nondrug-like space.
Zhao H
Drug Discov Today; 2011 Feb; 16(3-4):158-63. PubMed ID: 21147254
[TBL] [Abstract][Full Text] [Related]
15. Nuclear magnetic resonance in target profiling and compound file enhancement.
Sun C; Hajduk PJ
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):463-70. PubMed ID: 16889229
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and the drug-target residence time concept.
Dahl G; Akerud T
Drug Discov Today; 2013 Aug; 18(15-16):697-707. PubMed ID: 23500610
[TBL] [Abstract][Full Text] [Related]
17. Can cell systems biology rescue drug discovery?
Butcher EC
Nat Rev Drug Discov; 2005 Jun; 4(6):461-7. PubMed ID: 15915152
[TBL] [Abstract][Full Text] [Related]
18. AC biosusceptometry in the study of drug delivery.
Corá LA; Romeiro FG; Stelzer M; Américo MF; Oliveira RB; Baffa O; Miranda JR
Adv Drug Deliv Rev; 2005 Jun; 57(8):1223-41. PubMed ID: 15935871
[TBL] [Abstract][Full Text] [Related]
19. Residence time of receptor-ligand complexes and its effect on biological function.
Tummino PJ; Copeland RA
Biochemistry; 2008 May; 47(20):5481-92. PubMed ID: 18412369
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of molecular cancer therapeutics.
van Montfort RL; Workman P
Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
